John Park

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

Teri Kreisl, Lyndon Kim, Kraig Moore et al. · Journal of Clinical Oncology · 2008 · 1.6K citations · Full text

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

Alexander M. Menzies, Douglas B. Johnson, Sangeetha Ramanujam et al. · Annals of Oncology · 2016 · 811 citations · Full text

Autoimmune Disorders, Autoimmune Disease, Anti-pd-1 Therapy +10

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

Jennifer L. McQuade, Carrie R. Daniel, Kenneth R. Hess et al. · The Lancet Oncology · 2018 · 647 citations · Full text

Oncology, Body Composition, Cancer Management +8

Meckel Diverticulum

John Park, Bruce G. Wolff, Matthew K. Tollefson et al. · Annals of Surgery · 2005 · 606 citations · Full text

A specific antidote for dabigatran: functional and structural characterization

Felix Schiele, Joanne van Ryn, Keith A. Canada et al. · Blood · 2013 · 560 citations · Full text